140 related articles for article (PubMed ID: 23233357)
1. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
Lucioni C; D'Ambrosi A; Mazzi S; Pollesello P; Apajasalo M; Fedele F
Adv Ther; 2012 Dec; 29(12):1037-50. PubMed ID: 23233357
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
3. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
4. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
5. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
[TBL] [Abstract][Full Text] [Related]
6. Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case.
Mardiguian S; Kivikko M; Heringlake M; Smare C; Bertranou E; Apajasalo M; Pollesello P
J Med Econ; 2016; 19(5):506-14. PubMed ID: 26707159
[TBL] [Abstract][Full Text] [Related]
7. [Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
Oliveira MT; Follador W; Martins ML; Canaviera R; Tsuji RL; Scipioni A; Barretto AC
Arq Bras Cardiol; 2005 Jul; 85(1):9-14. PubMed ID: 16041448
[TBL] [Abstract][Full Text] [Related]
8. Inotropes and cardiorenal syndrome in acute heart failure - A retrospective comparative analysis.
Madeira M; Caetano F; Almeida I; Fernandes A; Reis L; Costa M; Gonçalves L
Rev Port Cardiol; 2017 Sep; 36(9):619-625. PubMed ID: 28826934
[TBL] [Abstract][Full Text] [Related]
9. Levosimendan: a retrospective single-center case series.
Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
[TBL] [Abstract][Full Text] [Related]
10. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
13. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu Y
Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
[TBL] [Abstract][Full Text] [Related]
14. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
15. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
Duygu H; Ozerkan F; Nalbantgil S; Zoghi M; Akilli A; Akin M; Nazli C; Ergene O
Int J Cardiol; 2008 Jan; 123(2):201-3. PubMed ID: 17316845
[TBL] [Abstract][Full Text] [Related]
16. Pharmaco-economics of levosimendan in cardiology: a European perspective.
Nieminen MS; Buerke M; Parissis J; Ben-Gal T; Pollesello P; Kivikko M; Karavidas A; Severino P; Comín-Colet J; Wikström G; Fedele F
Int J Cardiol; 2015 Nov; 199():337-41. PubMed ID: 26241640
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan compared with dobutamine in low output patients.
Nieminen MS
Minerva Anestesiol; 2003 Apr; 69(4):258-63. PubMed ID: 12766717
[TBL] [Abstract][Full Text] [Related]
18. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trials with levosimendan.
Mebazaa A; Barraud D; Welschbillig S
Am J Cardiol; 2005 Sep; 96(6A):74G-9G. PubMed ID: 16181826
[TBL] [Abstract][Full Text] [Related]
20. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]